A cross-sectional assessment to detect type 2 diabetes with endothelial and autonomic nervous system markers using a novel system

Journal of Diabetes & Metabolic Disorders

Karyem H Aliffe¹  Eduard Tiozzo²  Judi M Woolger³  Janet Konefal²  Sacha Medici²  Sharon Goldberg⁴  Armando Mendez³  Johanna Lopez²  Steven E Atlas²  Laura Lantigua²  John E Lewis² 

[1] Pharmacognosia, Rainier 98576, WA, USA;Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Suite #1474 (D28), Miami 33136, FL, USA;Department of Medicine, University of Miami Miller School of Medicine, Miami 33136, FL, USA;Division of Hospital Medicine, University of Miami Miller School of Medicine, Miami 33136, FL, USA

关键词: Oral glucose tolerance test;    Glycosylated hemoglobin;    Cardiometabolic risk;    Autonomic nervous system;    Diabetic autonomic neuropathy;    Type 2 diabetes mellitus;   

Others  :  1135792
DOI  :  10.1186/s40200-014-0118-x

 received in 2014-07-23, accepted in 2014-12-01,  发布年份 2014

【 摘 要 】

Background

Type 2 diabetes mellitus is frequently unrecognized until complications appear. Diabetic autonomic neuropathy is one of the early complications of type 2 diabetes mellitus, resulting in autonomic nervous system (ANS) dysfunction. The purpose of this study was to determine the validity of ANS function indicators to screen for type 2 diabetes mellitus, as measured by the TM-Oxi and SudoPath system.

Methods

All enrolled participants completed a basic sociodemographic and medical history questionnaire including current medications. Healthy controls (n = 25) underwent a 2-hour oral glucose tolerance test (OGTT) to evaluate glucose, insulin, and insulin C-peptide. Patients with type 2 diabetes mellitus (n = 24) were assessed with fasting plasma glucose (FPG) and glycosylated hemoglobin. The TM-Oxi and SudoPath system evaluation was completed by all subjects. Data were analyzed using SPSS 22. Frequency and descriptive statistics were calculated on all variables. The criterion for statistical significance was α = 0.05.

Results

The twenty-five healthy controls had a mean age of 37.0 years. The twenty-four type 2 diabetes mellitus patients currently undergoing standard treatment had a mean age of 48.9 years. Based on the American Diabetes Association guidelines, we detected pre-diabetes in 4 subjects and diabetes in 1 subject, while all other subjects had normal FPG values. At 120 minutes, the correlations between the OGTT and cardiometabolic risk score (CMRS) were: r = 0.56 (p = 0.004) for glucose and r = 0.53 (p = 0.006) for insulin. At 120 minutes, the correlations between the OGTT and photoplethysmography index (PTGi) were: r = -0.56 (p = 0.003) for glucose and r = -0.41 (p = 0.04) for insulin. The CMRS, PTGi, and plethysmography total power index (PTGVLFi) differed significantly between the diabetes patients and healthy participants. The specificity and sensitivity for the CMRS, PTGi, and PTVLFi comparing the diabetes patients with healthy controls were high.

Conclusion

The TM-Oxi and SudoPath system shows promise as a valid, convenient, and non-invasive screening method for type 2 diabetes mellitus. The ANS function and CMR indicators measured by this system may be useful in guiding diabetes and cardiovascular health screening, treatment, and monitoring.

【 授权许可】

   
2014 Lewis et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar F, Stevens GA, Lim SS, Riley LM, Ezzati M: National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011, 377:568-577.
• [2]Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF: Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290:1884-1890.
• [3]Centers for Disease Control and Prevention: National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA; 2011.
• [4]D’Elia JA, Bayliss G, Roshan B, Maski M, Gleason RE, Weinrauch LA: Diabetic microvascular complications: possible targets for improved macrovascular outcomes. Int J Nephrol Renov Dis 2011, 4:1-15.
• [5]American Diabetes Association: Standards of medical care in diabetes--2011 Diabetes Care 2011, 34(Suppl 1):S11-S61.
• [6]Gnanadesigan E, Anand P, Balumahendran K, Gnanagurudasan E: Autonomic nervous system and type 2 diabetes mellitus. Asian J Biomed Pharm Sci 2013, 3:4-9.
• [7]Vinik AI: Diagnosis and management of diabetic neuropathy. Clin Geriatr Med 1999, 15:293-320.
• [8]Vinik AI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553-1579.
• [9]Stansberry KB, Hill MA, Shapiro SA, McNitt PM, Bhatt BA, Vinik AI: Impairment of peripheral blood flow responses in diabetes resembles an enhanced aging effect. Diabetes Care 1997, 20:1711-1716.
• [10]Stansberry KB, Peppard HR, Babyak LM, Popp G, McNitt PM, Vinik AI: Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes: a new model for the pathogenesis of microvascular dysfunction. Diabetes Care 1999, 22:1549-1554.
• [11]American Diabetes Association, American Academy of Neurology: Report and recommendations of the San Antonio conference on diabetic neuropathy. Consens statement Diabetes 1988, 37:1000-1004.
• [12]Freeman R: The Peripheral Nervous System and Diabetes. In Joslin’s Diabetes Mellitus. Edited by Weir G, Kahn R, King G. Lippincott, Philadelphia; 2002.
• [13]Pfeifer MA, Weinberg CR, Cook DL, Reenan A, Halter JB, Ensinck JW, Porte D Jr: Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 1984, 7:447-453.
• [14]Schumer MP, Joyner SA, Pfeifer MA: Cardiovascular autonomic neuropathy testing in patients with diabetes. Diabetes Spectrum 1998, 11:227-231.
• [15]Ewing DJ, Martyn CN, Young RJ, Clarke BF: The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985, 8:491-498.
• [16]Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology: Heart rate variability. Standards of measurement, physiological interpretation, and clinical use Eur Heart J 1996, 17:354-381.
• [17]Rolim LC, de Souza JS, Dib SA: Tests for early diagnosis of cardiovascular autonomic neuropathy: critical analysis and relevance. Front Endocrinol (Lausanne) 2013, 4:173.
• [18]Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, Stevens M, Kempler P, Hilsted J, Tesfaye S, Low P, Valensi P: Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011, 27:639-653.
• [19]Alty SR, Ngarita-Jaimes N, Millasseau SC, Chowienczyk PJ: Predicting arterial stiffness from the digital volume pulse waveform. IEEE Trans Biomed Eng 2007, 54:2268-2275.
• [20]Anderson TJ: Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk. Can J Cardiol 2006, 22(Suppl B):72B-80B.
• [21]Stoner L, Young JM, Fryer S: Assessments of arterial stiffness and endothelial function using pulse wave analysis. Int J Vasc Med 2012, 2012:1-9.
• [22]Nousou N, Urase S, Maniwa Y, Fujimura K, Fukui Y: Classification of acceleration plethysmogram using self-organizing map.Intelligent Signal Processing and Communications Symposium 2006: 681-684.
• [23]Wilke K, Martin A, Terstegen L, Biel SS: A short history of sweat gland biology. Int J Cosmet Sci 2007, 29:169-179.
• [24]van’t RE E, Alssema M, Rijkelijkhuizen JM, Kostense PJ, Nijpels G, Dekker JM: Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. Diabetes Care 2010, 33:61-66.
• [25]Sacks DB: A1C versus glucose testing: a comparison. Diabetes Care 2011, 34:518-523.
• [26]Balkau B: Screening for diabetes. Diabetes Care 2008, 31:1084-1085.
• [27]Engelgau MM, Narayan KM, Herman WH: Screening for type 2 diabetes. Diabetes Care 2000, 23:1563-1580.
• [28]International Expert Committee: Report on the role of the A1C assay in the diagnosis of diabetes Diabetes Care 2009, 32:1327-1334.
• [29]Mostafa SA, Khunti K, Kilpatrick ES, Webb D, Srinivasan BT, Gray LJ, Davies MJ: Diagnostic performance of using one- or two-HbA1c cut-point strategies to detect undiagnosed type 2 diabetes and impaired glucose regulation within a multi-ethnic population. Diab Vasc Dis Res 2013, 10:84-92.
• [30]Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD: HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care 2001, 24:465-471.
• [31]Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100:1134-1146.
• [32]Meyer C, Milat F, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ: Vascular dysfunction and autonomic neuropathy in Type 2 diabetes. Diabet Med 2004, 21:746-751.
• [33]Jermendy G: Clinical consequences of cardiovascular autonomic neuropathy in diabetic patients. Acta Diabetol 2003, 40(Suppl 2):S370-S374.
• [34]Kim JA, Montagnani M, Koh KK, Quon MJ: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
• [35]Cameron JD, Cruickshank JK: Glucose, insulin, diabetes and mechanisms of arterial dysfunction. Clin Exp Pharmacol Physiol 2007, 34:677-682.